Top 50 Ai For Genomics

The startup has developed a digital diagnostics platform that utilizes artificial intelligence for genetic analysis and clinical decision support, enhancing the traceability and interoperability of bioinformatics data. This technology enables researchers and clinicians to efficiently access and reuse critical information, thereby expediting the diagnosis process for various diseases.

Emedgene utilizes AI algorithms to analyze genomic data for diagnostics and discovery, enabling healthcare providers to identify genetic conditions more efficiently. The platform enhances the accuracy of genomic interpretations, reducing the time and cost associated with traditional diagnostic methods.

The startup has developed a genome-analysis platform that facilitates the acquisition, analysis, and storage of genomic data without the need for repeated sequencing of the same genome for different tests. This technology enables healthcare providers to efficiently manage genetic data and deliver precise DNA sequencing services, enhancing the overall effectiveness of genomic research and patient care.

WhiteLab Genomics utilizes a proprietary platform that combines graph knowledge technology and machine learning to optimize the design of payloads and vectors for gene and cell therapies. This technology accelerates the development process, reducing costs and time to market for genomic medicines, making them more accessible to patients.

The startup develops gene therapies using artificial intelligence to enhance the design and optimization of genetic constructs. Their technology enables researchers to create more predictable and controllable gene therapies, facilitating faster development for various applications.

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

This company offers genomic data interpretation services to identify optimal cancer therapies based on individual patient sequencing. Their platform analyzes genomic data to provide personalized insights for cancer treatment and risk assessment. By combining data integration, predictive modeling, and visualization, they enable doctors to tailor surveillance and risk-reduction strategies for patients.

Genomenon develops the Mastermind Genomic Intelligence Platform, which utilizes AI to analyze and interpret extensive genomic datasets, providing actionable insights for clinical diagnostics and precision therapeutics. The platform enhances variant interpretation efficiency, enabling healthcare professionals to make informed decisions based on a comprehensive database of over 26 million curated genomic variants.

The startup has developed an artificial intelligence platform for biomarker discovery and sequencing analysis, focusing on extracting biosignatures from single-cell and multi-omics data. This platform enables physicians to efficiently analyze complex disease patterns, reducing data processing time and costs while enhancing insights for patient stratification.

Galatea Bio utilizes next-generation sequencing and a large-scale genomic-phenotypic data lake to facilitate precision health initiatives for diverse populations. The company addresses the need for comprehensive genetic testing and biobanking solutions that respect participant privacy while enabling advanced biomedical research.

GenBio AI develops the AI-Driven Digital Organism (AIDO), a unified system of multiscale foundation models for predicting, simulating, and programming biology. AIDO integrates diverse biological data from DNA to single-cell information, enabling holistic understanding and accelerating breakthroughs in drug discovery and bio-engineering.

This biotechnology company utilizes artificial intelligence to cultivate and evolve proteins essential for bio-products, enhancing the efficiency of medical research. By providing reliable and rapid access to these proteins, the company addresses the need for improved medical services in the healthcare sector.

OMGene uses AI to analyze genetic data, providing personalized recommendations for career development, mental well-being, and healthy aging. The platform delivers actionable insights based on individual genetic predispositions.

The startup employs AI algorithms to analyze genetic data for identifying mutations associated with hereditary diseases. This technology enables healthcare providers to deliver accurate diagnoses and tailored treatment plans for patients with genetic disorders.

Provides an integrated platform for low-pass whole genome sequencing, combining assay development, scalable sequencing, and cloud-based data analytics to deliver cost-effective genomic insights. Enables applications in human, plant, and animal genomics, such as predicting disease risk, identifying genetic traits, and optimizing breeding strategies, while streamlining data processing and management for researchers and industry professionals.

Metagenomi utilizes metagenomics and machine learning to discover and develop novel genome editing systems that enable precise modifications to the human genome. This technology addresses the limitations of existing gene editing methods by providing a versatile toolbox capable of targeting specific sites for therapeutic interventions.

SeqOne provides a clinical decision support platform that utilizes AI-driven bioinformatics to analyze next-generation sequencing (NGS) data for germline and somatic variants. The platform enhances diagnostic accuracy and efficiency by identifying complex genomic events that standard pipelines often overlook, thereby improving patient outcomes in precision medicine.

Deep Genomics utilizes a proprietary AI platform to analyze complex RNA biology data, identifying novel therapeutic targets for genetic conditions. By streamlining the drug discovery process, the company aims to develop RNA therapies that can precisely target genetic causes, significantly reducing the time and cost associated with traditional methods.

Enigma Genomics utilizes next-generation sequencing technologies and artificial intelligence to decode individual genomes, providing personalized genetic insights that inform health decisions. The platform enables users to access and control their genetic data for life, facilitating proactive disease prevention and tailored medical treatments.

The startup has developed a gene-editing technology that enables scalable digital genome engineering through a user-friendly interface. This technology produces low-cost libraries of thousands of designer protein and genome variants, each with specific and trackable mutations, facilitating efficient research and development in genetic engineering.

The startup operates a personal health and genomic data-sharing platform that connects users with researchers, enabling participation in studies on common and rare diseases. By allowing individuals to control their data and opt into research, the platform facilitates the collection of dynamic health and genetic datasets for personalized medicine.

Haplotype develops software that reduces genomic sequencing costs by 50% to 90% while utilizing polygenic risk models to predict, detect, and prevent diseases. The platform accelerates genetic analysis by streamlining workflows and eliminating the need for custom software pipelines.

Geneyx provides DNA and RNA data analysis and interpretation for whole genome sequencing (WGS), whole exome sequencing (WES), gene panels, and microarrays, enabling rapid transformation of raw genetic data into clinical reports. The platform enhances diagnostic accuracy and efficiency, aiming to eliminate undiagnosed diseases by increasing the diagnostic yield and reducing turnaround times for genetic testing.

The startup develops a genomics platform that enhances genetic testing accuracy by analyzing the functional significance of genetic variations and mutations in the human genome. This technology enables improved interpretation of genetic tests for rare diseases and cancer, facilitating the conversion of generic drugs into targeted precision medicines.

Accelerates precision medicine by leveraging advanced genomic analysis and machine learning to tailor treatments based on individual genetic profiles. This approach addresses the limitations of one-size-fits-all therapies, enabling more effective and personalized healthcare solutions.

This startup provides AI-powered software that accelerates biomedical discovery by automating data generation, analysis, and hypothesis testing. Their platform helps biotech and pharmaceutical scientists quickly derive insights from genomic data, significantly reducing the time and cost associated with traditional research methods.

The startup develops AI-powered precision medicine technology that utilizes multi-omics analysis to decode cellular health and identify molecular causes of diseases. This approach enhances early disease detection and enables targeted therapies for non-invasive prenatal and oncology testing.

GenoGra offers software solutions for genome analysis in research and clinical settings, leveraging genome graphs to represent genomic data. Their products use proprietary algorithms and hardware acceleration to provide accurate and high-performance analysis of genome variability.

Building genomic intelligence.

The startup utilizes polymathic AI to deliver precision medicine by analyzing complex biological data and patient information. This approach enhances treatment personalization, improving patient outcomes in healthcare by tailoring therapies to individual genetic profiles.

The startup develops a genotyping and sequencing platform that translates genetic data into clinical applications, enabling healthcare providers to make informed treatment decisions. This technology enhances patient care and biomedical research by improving the understanding and management of diseases.

The startup operates a genomics analytics platform that provides clinical genome reporting and AI-driven insights for monogenic and polygenic risk assessment, pharmacogenomics, and wellness traits. This technology enables healthcare providers to make informed decisions based on precise genomic data, enhancing patient care and research capabilities.

Gen AI for Clinical Trials utilizes generative artificial intelligence to optimize patient recruitment and data analysis in clinical research. This technology reduces trial timelines and costs by enhancing participant matching and streamlining data processing.

The startup utilizes artificial intelligence and genetic analysis to enhance healthcare innovation by identifying and developing targeted therapies. This approach addresses the inefficiencies in drug discovery and personalized medicine, aiming to accelerate the delivery of effective treatments to patients.

This microbiome-based life sciences company develops healthcare solutions using big data analytics, mathematical modeling, deep learning, and AI. Their technology analyzes the human microbiome to provide insights that support individual health and well-being.

Genz develops AI algorithms for genomic data analysis to facilitate personalized treatment plans for women with breast cancer. By leveraging advanced data analytics, the company aims to enhance the precision of therapeutic interventions tailored to individual genetic profiles.

This startup offers a clinical genome interpretation platform that uses AI algorithms to analyze genomic data from various sources. The platform delivers actionable genomic insights to medical professionals, enabling faster and more accurate diagnostic reports.

This startup provides an AI-powered blockchain platform for decentralized science, specifically focused on genomics. It offers researchers access to clean, labeled, and organized genetic profiles, accelerating the development of personalized, data-driven medical solutions and reducing time-to-market for genomics-based AI applications.

The startup operates a genomics platform that centralizes and integrates DNA data to provide precise diagnoses and personalized treatment plans through advanced data analysis and interpretation. By leveraging genomic information, the platform enables researchers to enhance health outcomes and preventive care strategies for individuals.

Almaden Genomics offers g.nome, a cloud-native platform that enables researchers to build low-code and no-code genomic workflows using a visual drag-and-drop interface. This platform streamlines the analysis of large genomic datasets, allowing teams to focus on scientific discovery while significantly reducing the time required to generate insights.

Develops user-friendly genomics software tools, including Circa for data visualization and 42basepairs for cloud-based genomic analysis. These tools streamline complex genomic workflows, enabling scientists to efficiently interpret and analyze large-scale genomic data without the steep learning curve typically associated with such software.

The startup operates a biomarker discovery platform that utilizes artificial intelligence and genomic analysis techniques to identify personalized cancer therapies for patients. This approach enhances patient stratification, enabling healthcare providers to deliver more effective treatment options tailored to individual needs.

XGenomes develops DNA sequencing technologies that utilize optical super-resolution imaging and machine learning to monitor health, detect early disease signals, and track interventions throughout an individual's life. Their platform addresses high error rates and complex workflows in existing sequencing methods, providing a streamlined and cost-effective solution for continuous health monitoring.

This startup provides a secure and customizable platform for genomic data analysis, optimizing compute architecture and standardizing bioinformatic algorithms for research, academia, and clinical stakeholders. By simplifying the complexities of genomic data processing, it enhances efficiency and accessibility for users in these fields.

enGenome offers the eVai platform, which utilizes AI and guideline-based classification to accurately interpret genomic variants for early diagnosis of rare diseases. This technology enhances clinical decision-making by providing precise genetic diagnoses, addressing the challenge of variant interpretation in translational research and routine healthcare.

This biotechnology company transforms genomic data into actionable insights for healthcare. It leverages GSA Microarray data technology to analyze and interpret genomic information, providing personalized nutrition recommendations and integrated patient management tools.

The startup offers a food selection platform that utilizes artificial intelligence to generate personalized food and ingredient recommendations based on users' biological and genomic profiles. By analyzing the macro, micro, and phytonutrient content of millions of foods, the platform provides tailored dietary options that align with individual health, nutrition, and taste requirements.

SIVOTEC BioInformatics offers the GENA AI platform, which automates the analysis of SNP Array genetic test data for rare disease identification. This platform helps commercial labs, hospitals, and academic centers accelerate diagnosis by significantly reducing the manual effort and time required to correlate genetic data with over 7,000 rare diseases.

This company analyzes individual genetic data to provide personalized health recommendations and treatment plans. By leveraging insights from a person's unique genetic makeup, they aim to optimize healthcare decisions for improved outcomes.

Amwise Diagnostic specializes in precision medicine technology that utilizes genomic profiling and biomarker analysis to tailor cancer treatment plans for individual patients. This approach enhances treatment efficacy and minimizes adverse effects by ensuring therapies are specifically matched to the unique genetic makeup of each tumor.